NINA Medical develops noninvasive surgery technologies, expanding the scope of next-generation medicine.
In noninvasive surgery, surgeon’s knife is replaced with a therapeutic beam of focused energy, directed to the diseased tissue (e.g. a tumor), providing local and selective therapy.
The technology eliminates the need to cut healthy tissue in order to get access to the diseased tissue, where treatment is required. Since tissue-disruption does not occur, bleeding and post-operative infections are absent, pain and overall trauma for the patient are greatly reduced.
For us, next generation medicine is about focal therapy – Treat. Don’t injure.
NINA Medical is committed to introduce innovative and affordable solutions that will increase the accessibility of high-quality medicine to the public.
As a result, more people will be able to receive the medical care they need.
High intensity focused ultrasound (HIFU) is the modality of choice for noninvasive surgery; ultrasound can travel long distances through soft tissue, nonetheless it can be focused into a small region in the body.
The intensity at the focal point can be made very high, sufficient to ‘burn’ a voxel of tissue. The result is a therapeutic beam, capable of remotely induce a controlled damage to selected tissue for medical purposes, e.g. tumor ablation.
NINA Medical‘s proprietary technology enables to image the HIFU beam in real-time, displaying the actual position and shape of the focal point in-situ. Implementing novel techniques in diagnostic ultrasound, visualization is achieved at very low HIFU intensities, far below the threshold for damage to tissue (“cold navigation”).
Having the focal point positioned on the target tissue, the system may be switched from “Navigation Mode” to “High Power Mode”, executing ablation to the diseased tissue.
Therefore, a closed-loop image-guided HIFU is provided. The technology is being implemented in an affordable medical device – the TriModal Transducer – for noninvasive surgery.
With 600,000 hysterectomy procedures in the US, about 50% of them related to symptomatic leiomyoma (uterine fibroids), the direct annual cost to the American market is estimated in $2.1B
Zohar Gendler, MSc, Chairman of the board
Shmuel Ben-Ezra, MSc, Founder and CEO
Yoni Hertzberg, PhD, MBA, Founder and CTO
Prof. Doron Kopelman, MD, Clinical Director